The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc’s aducanumab, a decision that will affect the future of Alzheimer’s disease research and treatment and show the agency’s willingness to approve badly needed medicines based on less than definitive data.

The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.

The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.

The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.

The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.

Two articles published by Alzheimer's & Dementia: Translational Research & Clinical Interventions show substantial changes in the focus and funding of clinical trials for Alzheimer's disease therapies. The newly published articles throw a greater spotlight on a decision—now before the U.S. Food and Drug Administration (FDA)—that would potentially bring a new drug therapy to Alzheimer's patients for the first time in nearly 20 years.

Nonprofit organizations and public agencies have picked up the slack and are funding increased numbers of clinical trials to drive growth and innovation in an area where there is pressing unmet medical need.

Two newly published articles throw a greater spotlight on a decision -- now before the U.S. Food and Drug Administration (FDA) -- that would potentially bring a new drug therapy to Alzheimer's patients for the first time in nearly 20 years.

It’s estimated that one in nine people older than 65 in Nevada live with Alzheimer’s disease. The state also ranks as the 3rd fastest growing dementia population in the country.

A new study endeavor will explore US Food and Drug Administration (FDA) approved medications for efficacy in Alzheimer disease.

Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s.

AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.